Virgo Public Relations
Investor RelationsPublished November 20, 20267 min read

PIPE and Registered Direct Offerings: 4 Announcements

By Kyle Porter, Executive Vice President & Managing Director.

Updated November 20, 2026

Follow on LinkedIn ↗
PIPE and Registered Direct Offerings: 4 Announcements
Key takeaway

PIPE and registered direct offering announcements compared across Amesite, Acurx, Citius and Enveric: headline sizes, upfront cash, warrants and legends.

A PIPE or registered direct offering announcement tells investors how much a public company is raising, at what price, with which warrants and when the deal closes. Four 2026 announcements, from Amesite, Acurx, Citius and Enveric, show how issuers chose between headline totals and upfront cash, how they described warrants, and how they tied the raise to company plans.

Updated November 8, 2026

Contents

What are PIPE and registered direct offerings?

A registered direct offering sells registered shares directly to selected investors, usually off an existing shelf registration. A PIPE, or private investment in public equity, sells unregistered securities to investors in a private placement. Many recent deals combine both: shares sold in a registered direct offering, with warrants issued at the same time in a concurrent private placement. All four announcements below follow that pattern.

The announcement for such a deal typically needs to cover the following:

  • Size and price: the headline amount, the number of shares and the price per share.

  • Warrants: how many, at what exercise price and for how long.

  • Proceeds: the gross amount upfront and any amount that depends on warrant exercise.

  • Use of proceeds: what the company will do with the money.

  • Intermediaries: the placement agent and where to get the prospectus supplement.

  • Timing: expected closing and any approvals still needed.

  • Legends: the statements that the release is not an offer to sell, and the forward-looking statement language.

Offering communications for public companies are shaped by securities rules that this page does not attempt to explain, and counsel should review every release. Related background is in the guides to Regulation FD for investor relations and Regulation A offering communications, and the financial public relations hub collects the wider set. Each case below is described from the company's own release or filing.

How did Amesite and Acurx headline "up to" amounts?

Amesite and Acurx both led with a larger "up to" figure that includes money that arrives only if warrants are exercised. The cash the company receives at closing is smaller, and each release states it in the subheading or opening lines.

Amesite announced on April 27, 2026 an offering described in its headline as up to $6 million, a concurrent registered direct offering and private placement priced at-the-market under Nasdaq rules. The Amesite SEC exhibit states that $2 million is upfront, with up to approximately $4 million more from the exercise of warrants in full. It describes Series A-1 and A-2 warrants that expire eighteen months after the later of the effective date of a resale registration statement and the date of stockholder approval, names H.C. Wainwright as placement agent and says the warrants are unregistered, offered in a private placement.

Acurx Pharmaceuticals announced on April 16, 2026 a registered direct offering of up to $7.1 million, again priced at-the-market under Nasdaq rules. The Acurx press release says $2.5 million is upfront, with up to an additional $4.6 million if the short-term warrants are exercised in full on a cash basis. The warrants carry an exercise price of $2.78, are immediately exercisable and expire twenty-four months after the effective date of the resale registration. The release also tells readers its lead antibiotic candidate is Phase 3 ready subject to obtaining appropriate financing, which links the raise to a specific milestone.

The communications trade-off is plain. A larger headline signals scale, but a careful reader sees that most of the total is contingent. Both companies included the upfront amount and the warrant dependency prominently, which limits the risk of the headline being read as cash on hand.

How did Citius and Enveric frame smaller raises?

Citius and Enveric headlined the cash raised at closing and described warrants in the body. Their approach gives a simpler headline, with the warrant terms available for readers who look further.

Citius Pharmaceuticals announced on April 24, 2026 a registered direct offering of $5 million, priced at-the-market under Nasdaq rules. According to the release as published on the BioSpace release page, the company agreed to sell 5,076,143 shares, or pre-funded warrants in lieu of shares, at $0.985 per share, with a concurrent private placement of warrants for the same number of shares at an exercise price of $0.86. H.C. Wainwright acted as exclusive placement agent. The release states that proceeds would support the commercial launch of LYMPHIR, including milestone and regulatory payments, along with development initiatives and general corporate purposes. Tying the use of proceeds to a named product gives investors a concrete reason for the raise.

Enveric Biosciences announced on January 28, 2026 a $1.5 million registered direct offering priced at-the-market under Nasdaq rules, selling 328,802 shares at $4.41. The closing release stated that concurrent private placement warrants, designated Series G and Series H, covered up to 328,802 shares each, and that the Series H warrants had an exercise price of $4.16 and expired eighteen months after the effective date of the resale registration. H.C. Wainwright was again the exclusive placement agent. The company said it intended to use net proceeds for product development, working capital and general corporate purposes, which is a broad statement compared with Citius.

All four releases share a feature that is easy to miss: the same placement agent and the same structure. That consistency suggests the format is largely standardized, so differences in headline choice and use-of-proceeds detail are where an issuer can communicate most clearly.

How do the four announcements compare?

The table sets out the key facts as stated in each company's materials. The headline choice column is an editorial characterization.

CompanyDateHeadline figureUpfront cashWarrants describedHeadline choice

AmesiteApr 27, 2026Up to $6 million$2 millionSeries A-1 and A-2; about $4 million more if exercised in full; expire 18 months after later of resale effectiveness and stockholder approvalTotal including warrants AcurxApr 16, 2026Up to $7.1 million$2.5 millionShort-term warrants at $2.78; up to $4.6 million more; expire 24 months after resale effectivenessTotal including warrants CitiusApr 24, 2026$5 million$5 millionWarrants at $0.86 for 5,076,143 shares, in concurrent private placementUpfront cash only EnvericJan 28, 2026$1.5 million$1.5 millionSeries G and H warrants for up to 328,802 shares each; Series H at $4.16, 18 monthsUpfront cash only

The pattern is clear. Two issuers led with totals that include warrant exercise and two led with cash raised, and all four disclosed the structure and the placement agent. The choice affects how a reader perceives the size of the raise, which is why the upfront amount should always appear near the top.

What can an issuer copy from these announcements?

An issuer can copy structure and discipline, not wording. The checklist below is an editorial reading of the four cases, and securities counsel should shape any real release.

  • State the upfront cash amount in the first lines, even if the headline includes warrant proceeds.

  • Describe warrants plainly: number, exercise price, term and any approval conditions.

  • Name the placement agent and say how to obtain the prospectus supplement.

  • Tie the use of proceeds to a specific program or milestone where possible.

  • Give the expected closing date and confirm the closing in a separate release.

  • Include the standard legends and forward-looking statement language.

  • Prepare investor questions about dilution and pricing before the release goes out.

Frequently asked questions

What is a registered direct offering?

It is an offering of registered shares sold directly to selected investors, typically off a shelf registration, without a broad public marketing effort.

What is a PIPE?

A private investment in public equity is a sale of unregistered securities of a public company to investors in a private placement. Resale registration usually follows.

What does priced at-the-market under Nasdaq rules mean?

It refers to pricing set in relation to Nasdaq's listing rules. The exact meaning and its effect on approvals are legal questions for counsel, and some releases note that warrants are exercisable after stockholder approval.

Why do some headlines say up to a larger amount?

They include proceeds that would arrive only if warrants are exercised in full. The upfront cash is smaller, which is why good releases state both.

Yes. Offering communications are governed by securities laws, so counsel should review the release, the legends and the timing before publication.

Editorial disclosure and research notes

Facts about each offering come from the companies' own releases: the Amesite SEC exhibit, the Acurx PR Newswire releases, the Citius release as published by BioSpace, and the Enveric opening and closing releases. The Enveric details were read through reproductions of its releases. Statements about the pattern and the checklist are editorial judgment by Virgo PR, not legal advice or investment advice. Virgo PR publishes this page and does not claim involvement in any of these offerings, and none of the companies is recommended or criticized.

This page is general information and is not legal advice. Public companies should consult securities counsel before relying on it, and this page is flagged for counsel review.

Follow us

LinkedIn
Contact

Let's make
noise.

Send a note. The senior team reads every inbound, no junior filter, no auto-pitch.

Phone

Phone

212.584.4289
Social

Social

24-hour response, every weekday
Confidential, NDAs available on request
Retainers from around $10,000 per month, 4 month minimum

Start the conversation